Literature DB >> 7173181

Sensitivity of 341 non-fermentative gram-negative bacteria to seven beta-lactam antibiotics.

P C Appelbaum, J Tamim, J Stavitz, R C Aber, G A Pankuch.   

Abstract

Susceptibility of 341 isolates of non-fermentative gram-negative bacteria to carbenicillin, piperacillin, cefoperazone, moxalactam, cefotaxime, ceftizoxime, and N-formimidoyl thienamycin was determined by the agar dilution and disc diffusion methods. Piperacillin was the most active agent against Pseudomonas aeruginosa, thienamycin the most active against Pseudomonas fluorescens and Pseudomonas putida, and moxalactam the most active against Pseudomonas maltophilia. Piperacillin and thienamycin were the most active agents against the other Pseudomonas species studied. Thienamycin proved to have excellent activity against Acinetobacter calcoaceticus--90% of strains were inhibited by less than or equal to 1 microgram/ml. The two most active drugs against Alcaligenes species were piperacillin and thienamycin, both of which inhibited 90% of isolates at a concentration of 2 micrograms/ml. All drugs were active against Moraxella species. The broad sensitivity spectrum of piperacillin, thienamycin, and the third-generation cephalosporins against non-fermentative gram-negative bacteria indicates their potential use in infections caused by these organisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173181     DOI: 10.1007/bf02019617

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  14 in total

1.  Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin.

Authors:  D Phaneuf; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  In-vitro antibacterial activity of cefoperazone, a piperazine cephalosporin.

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-08       Impact factor: 5.790

3.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

5.  In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

7.  Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).

Authors:  A L Barry; C Thornsberry; R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

View more
  10 in total

1.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

3.  Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.

Authors:  M A Visalli; M R Jacobs; T D Moore; F A Renzi; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 4.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

5.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

Review 8.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

10.  [Calculated initial chemotherapy in mechanically-ventilated postoperative patients with peritonitis, sepsis and pneumonia].

Authors:  G Hünefeld; H Weissbrodt; H Aebert; H Bunzendahl
Journal:  Infection       Date:  1986       Impact factor: 3.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.